welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Thetis Pharmaceuticals Awarded Key Patent on HEALER Technology
Thetis Pharmaceuticals LLC, a privately-held biopharmaceutical company focused on gastrointestinal and cardiometabolic diseases, announced today that the USPTO has granted patent US 9,242,008 providing composition of matter protection for two Thetis development candidates, TP-252 for familial adenomatous polyposis and TP-452 for dyslipidemia. The allowed claims include pharmaceutical compositions that are mineral amino-acid based derivatives of fatty acids. National filings outside of the United States are underway.
expertly curated content related to this topic
- Chemoprevention of Colorectal Cancer: Systematic Review and Economic EvaluationBACKGROUND : Colorectal cancer (CRC) is ...
- @TravisHBrayA research chemist in my previous life, ...
- Neha Patel, MDAssistant Professor, Internal Medicine a...
- In a Select Group of Patients Meeting Strict Clinical Criteria and Undergoing Ileal Pouch-Anal Anastomosis, the Omis...PURPOSE : Ileal pouch-anal anastomosis i...
- Therapeutic Approaches for Patients with Coexisting Familial Adenomatous Polyposis and Colorectal CancerColorectal cancer is a major cause of de...
- CEO Jeff Jacob Talks About FAP Trial (Familial Adenomatous Polyposis)https://www.youtube.com/watch?v=abPLjl6B...
- Melanie D. Baxter, ScMMelanie is a Clinical Cancer Genetic Cou...
English
Portuguese